All In Biotech

Investigational drug · Phase 2

RESP303

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-Cystic Fibrosis Bronchiectasis.

Phase 2

Last checked: Nov 19, 2026Latest source record: Mar 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "RESP303"

First trial start

2024

Oct 16, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "RESP303", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Non-Cystic Fibrosis Bronchiectasis

Approved drugs for the same conditions: Cystic fibrosis · Respiratory

Largest trials

Live from ClinicalTrials.gov: studies naming "RESP303" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Non-Cystic Fibrosis Bronchiectasis

  • HSK31858Phase 33 trials

    Haisco Pharmaceutical Group Co., Ltd. · Non-cystic Fibrosis Bronchiectasis, Asthma Bronchiale, Bronchiectasis

  • GalvokimigUCB9741Phase 23 trials

    UCB · Chronic Obstructive Pulmonary Disease With Chronic Bronchitis, Atopic Dermatitis, Non-cystic Fibrosis Bronchiectasis

  • CSL787Phase 21 trial

    CSL Behring · Non-cystic Fibrosis Bronchiectasis

  • RESP302Phase 21 trial

    Thirty Respiratory Limited · Non-Cystic Fibrosis Bronchiectasis

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.